Innovent Biologics Inc

Company Profile

• Business description

  Innovent Biologics is one of the leading biotechnology companies in China. Listed on the Hong Kong Stock Exchange in 2018, Innovent has 12 commercialized oncology products and four commercialized nononcology products as of January 2026, and 34 drugs in its research and development pipeline. Its core assets are Tyvyt, a PD-1 inhibitor included in the National Reimbursement Drug Lists (NRDL) for the first-line treatment of five major cancers, and mazdutide, a GLP-1/glucagon dual agonist drug for weight loss, fat breakdown, and Type 2 diabetes. Mazdutide is the first domestic GLP-1 drug produced and competes with Eli Lilly and Novo Nordisk in China. Tyvyt’s main competition includes drugs from Junshi, Jiangsu Hengrui, BeOne, Merck, and Bristol Myers.

• Contact

  168 Dongping Street
  Suzhou Industrial Park
  Jiangsu Province
  Suzhou215123
  CHN

  T: +86 51269566088

  https://www.innoventbio.com

• Sector

  Healthcare

  Stock type

  Defensive

• Industry

  Biotechnology

  Fiscal Year End

  31 December 2026

  Employees

  8,754